Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort.

Mayo Clin Proc Innov Qual Outcomes · 2026 · PMC12993020 · PMID 41853136

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in Cox regression analysis, the difference in dialysis risk between SGLT2i users and tolvaptan users did not reach statistical significance (HR, 0.71; 95% CI, 0.37-1.39).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.